© 2025 MJH Life Sciences™ , Patient Care Online – Primary Care News and Clinical Resources. All rights reserved.
Sydney Jennings
Articles
Kelly Moore, MD, MPH, is Concerned About COVID-19 Vaccination Equity in Post-Universal Coverage America
October 02, 2025
Moore describes the ACIP's shared decision making approach to COVID-19 vaccination as a "passive recommendation" that will surely exclude at-risk US populations.
Weekly Dose Podcast: Arrhythmias as Early Risk Markers, Flu Vaccine Safety, Salt Substitute Use, Preconception CT Risks, and Global Diabetes Care Gaps
October 02, 2025
Today's episode highlights arrhythmias as CVD risk markers, influenza vaccine safety, salt substitute use, preconception CT risks, and global diabetes gaps.
9 Clinical Signs and Symptoms of Migraine Prodrome: At-a-Glance for Primary Care
October 02, 2025
The premonitory constellation of neurologic, autonomic, and behavioral symptoms are increasingly understood as the earliest manifestations of migraine pathophysiology.
Phase 3 VESALIUS-CV Trial Demonstrates Evolocumab Reduces Cardiovascular Events in High-Risk Adults Without Prior Heart Attack or Stroke
October 02, 2025
Evolocumab significantly reduced major cardiovascular events in high-risk patients without prior heart attack or stroke, making it the first PCSK9 inhibitor with proven benefit in both primary and secondary prevention.
10 Must-See Sessions for Primary Care Physicians at FMX 2025
October 02, 2025
Preview the top sessions at the AAFP Family Medicine Experience (FMX) 2025. From vaccines and obesity care to dementia and LGBTQ+ health, here are 10 highlights for family physicians.
Linus Health Will Highlight Digital Innovations in Early Detection of Cognitive Decline at FMX 2025
October 02, 2025
Linus Health will demonstrate advances in remote assessment platforms and digital biomarkers of cognitive health that can bring precision medicine to primary care.
Novartis' Oral Targeted BTKi Treatment Approved for Chronic Spontaneous Urticaria in Adults
October 02, 2025
Remibrutinib is the first oral BTK inhibitor for chronic spontaneous urticaria, with a dual mechanism of action that blocks 2 key autoimmune mechanisms.
FDA Grants Fast Track Designation to Anti-MTBR Tau Antibody BMS-986446 for Alzheimer Disease
October 01, 2025
The FDA has granted fast track designation to BMS-986446, an anti–microtubule binding region tau antibody in phase 2 trials for early Alzheimer disease.
Lipocine Updates Progress on Phase 3 Clinical Trial in Postpartum Depression with LPCN 1154
October 01, 2025
Lipocene expects to announce interim safety data from the study this quarter and said the phase 3 program results will support the company's NDA in 2026.
Suboptimal Risk Factor Levels are Nearly Universal at Onset of CVD, Study of 10 Million Reveals
October 01, 2025
The binational cohort study of exposure to 4 traditional CVD risk factors over time revealed that 99% of CVD events were preceded by suboptimal levels of at least one.